iBio-logo.jpg
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
September 27, 2021 07:30 ET | iBio, Inc.
Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming® and GlycaneeringTM...
iBio-logo.jpg
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
September 20, 2021 16:30 ET | iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio-logo.jpg
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
September 20, 2021 07:30 ET | iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio-logo.jpg
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET | iBio, Inc.
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio-logo.jpg
iBio Appoints William D. Clark to its Board of Directors
August 26, 2021 07:00 ET | iBio, Inc.
BRYAN, Texas, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
iBio-logo.jpg
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
August 25, 2021 07:30 ET | iBio, Inc.
– iBio licenses a novel antibody targeting regulatory T cells – – Company secures option to license additional antibodies developed with RubrYc’s predictive algorithms – – iBio acquires an equity...
iBio-logo.jpg
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
July 15, 2021 17:10 ET | iBio, Inc.
BRYAN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that...
iBio-logo.jpg
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
July 08, 2021 16:15 ET | iBio, Inc.
BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step...
iBio-logo.jpg
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink
June 09, 2021 16:30 ET | iBio, Inc.
BRYAN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today the...
iBio-logo.jpg
iBio to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 16:30 ET | iBio, Inc.
BRYAN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that...